Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2018.3958
Abstract: Importance A phase 2 trial comparing talimogene laherparepvec plus ipilimumab vs ipilimumab monotherapy in patients with advanced unresectable melanoma found no differential benefit in progression-free survival (PFS) but noted objective response rates (ORRs) of 38.8%… read more here.
Keywords: talimogene laherparepvec; life; laherparepvec plus; plus ipilimumab ... See more keywords
Review of Talimogene Laherparepvec (T-VEC): A First in Class Oncolytic Viral Treatment of Advanced Melanoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2020.01.039
Abstract: Talimogene laherparepvec (T-VEC) is an oncolytic virus based on herpes simplex virus type-1 approved for intralesional treatment of advanced melanoma. In this article, we review the clinical literature on T-VEC for advanced melanoma and provide… read more here.
Keywords: advanced melanoma; talimogene laherparepvec; treatment advanced; laherparepvec vec ... See more keywords
Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
Sign Up to like & getrecommendations! Published in 2017 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2017.02.003
Abstract: MCC: Merkel cell carcinoma MCPyV: Merkel cell polyomavirus PET/CT: position emission tomography/ computed tomography PD: programmed death TVEC: talimogene laherparepvec UV: ultraviolet INTRODUCTION Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy with a… read more here.
Keywords: merkel cell; cell carcinoma; cell; talimogene laherparepvec ... See more keywords
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0530-6
Abstract: Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB–IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients… read more here.
Keywords: melanoma; pseudo progression; response; talimogene laherparepvec ... See more keywords
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000399
Abstract: Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery. We aim to describe the safety… read more here.
Keywords: stage iiib; talimogene laherparepvec; treatment; safety ... See more keywords
A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15450
Abstract: Talimogene laherparepvec (T‐VEC) is approved for the treatment of unresectable melanoma in the USA, Europe, and Australia. This phase I, multicenter, open‐label, dose de‐escalation study evaluated the safety and efficacy of T‐VEC in Japanese patients… read more here.
Keywords: safety; talimogene laherparepvec; japanese patients; safety efficacy ... See more keywords
Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in‐transit melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cutaneous Pathology"
DOI: 10.1111/cup.13332
Abstract: Talimogene laherparepvec (T‐VEC) is a novel intralesional oncolytic genetically modified herpes simplex virus type 1 vector for the treatment of unresectable cutaneous, subcutaneous, and nodal melanoma. Although immunological therapies such as T‐VEC offer therapeutic promise,… read more here.
Keywords: melanoma; response; talimogene laherparepvec; treatment ... See more keywords
Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cutaneous Pathology"
DOI: 10.1111/cup.14094
Abstract: Talimogene laherparepvec (TVEC) is a genetically modified herpes simplex virus‐1 approved as an intralesional oncolytic immunotherapy for the treatment of advanced melanoma. Cutaneous reactions at the site of injection may mimic recurrent or progressive melanoma;… read more here.
Keywords: melanoma; talimogene laherparepvec; reaction mimicking; pseudolymphomatous reaction ... See more keywords
Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions – a case series
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.16922
Abstract: Talimogene laherparepvec (T-VEC) is a genetically engineered herpes simplex virus type 1 (HSV-1) and used in locally advanced melanoma patients. Its mode of action is not fully understood. We present three cases where T-VEC caused… read more here.
Keywords: laherparepvec initiate; talimogene laherparepvec; plasma cell; initiate plasma ... See more keywords
409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0409
Abstract: Background Peritoneal surface dissemination (PSD) of gastrointestinal and ovarian cancers carries a poor prognosis. Although cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy has emerged as a treatment option for this patient population, only a minority… read more here.
Keywords: medicine; talimogene laherparepvec; treatment; peritoneal surface ... See more keywords
Abstract OT-13-01: A phase I study of preoperative ipilimumab, nivolumab, and talimogene laherparepvec for localized breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-ot-13-01
Abstract: Background: Immunotherapy has emerged as a novel therapeutic strategy in many solid malignancies. In breast cancer, treatment with checkpoint inhibitors alone showed minimal response rates, likely because breast cancers are not sufficiently immunogenic to induce… read more here.
Keywords: ipilimumab; talimogene laherparepvec; cancer; study ... See more keywords